Abstract
Therapeutic communities have a long history, dating back to the Middle Ages. Beginning in the mid 20th century, the therapeutic community was revived in the form of such programs as Synanon, led by former substance abusers. Subsequent TCs have built upon the early principles of Synanon but adapted to meet the changing needs of clients and incorporated what has been learned from the expansion of the knowledge base of substance abuse treatment. Most notably, psychiatrists have come to play an important role as medical directors of TCs. This paper describes the adolescent treatment program at Daytop Village in terms of its functioning and patient population, and the role of the psychiatrist-medical director. Necessary adaptations to the TC model for adolescents are explained. The literature on outcome of this type of treatment with respect to adolescents is reviewed. The evidence suggests that therapeutic communities are an effective form of treatment for adolescent substance abusers.
Keywords: Adolescent substance abuse related disorders/treatment, therapeutic community, adolescents, residential treatment, Synanon, substance abusers, TCs, substance abuse treatment, adaptations, Daytop Village
Adolescent Psychiatry
Title: The Therapeutic Community for the Adolescent Substance Abuser
Volume: 1 Issue: 2
Author(s): Gregory C. Bunt and Britta Muehlbach
Affiliation:
Keywords: Adolescent substance abuse related disorders/treatment, therapeutic community, adolescents, residential treatment, Synanon, substance abusers, TCs, substance abuse treatment, adaptations, Daytop Village
Abstract: Therapeutic communities have a long history, dating back to the Middle Ages. Beginning in the mid 20th century, the therapeutic community was revived in the form of such programs as Synanon, led by former substance abusers. Subsequent TCs have built upon the early principles of Synanon but adapted to meet the changing needs of clients and incorporated what has been learned from the expansion of the knowledge base of substance abuse treatment. Most notably, psychiatrists have come to play an important role as medical directors of TCs. This paper describes the adolescent treatment program at Daytop Village in terms of its functioning and patient population, and the role of the psychiatrist-medical director. Necessary adaptations to the TC model for adolescents are explained. The literature on outcome of this type of treatment with respect to adolescents is reviewed. The evidence suggests that therapeutic communities are an effective form of treatment for adolescent substance abusers.
Export Options
About this article
Cite this article as:
C. Bunt Gregory and Muehlbach Britta, The Therapeutic Community for the Adolescent Substance Abuser, Adolescent Psychiatry 2011; 1 (2) . https://dx.doi.org/10.2174/2210676611101020122
DOI https://dx.doi.org/10.2174/2210676611101020122 |
Print ISSN 2210-6766 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-6774 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurotrophic Factor Treatment After Spinal Root Avulsion Injury
Central Nervous System Agents in Medicinal Chemistry Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Progress and Obstacles in the Application of Precision Medicine in the Management of Hepatocellular Carcinoma
Clinical Cancer Drugs Lipid Lowering Agents, Inflammation and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Prolonged Release of Anti-Retroviral Efavirenz From System Using ZIF-8 as Carrier
Current HIV Research Proteomic Analysis of Glioma Chemoresistance
Current Neuropharmacology Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective
Current Medicinal Chemistry SCYPPred: A Web-Based Predictor of SNPs for Human Cytochrome P450
Protein & Peptide Letters The GH/IGF-1 Axis and Heart Failure
Current Cardiology Reviews Safety Profile of the Use of Second Generation Antipsychotics in the Child and Adolescent Population
Current Psychopharmacology Meet Our Editorial Board Member:
Current Neuropharmacology Medico-Legal Issues with CTG Interpretation
Current Women`s Health Reviews Quantum Chemical Assessment of the Interaction of Potential Anticorrosion Additives with Steel Surface
Innovations in Corrosion and Materials Science (Discontinued) Conference Report: 8<sup>th</sup> Clinical Trials on Alzheimer Disease (CTAD), Barcelona, Spain November 5-7, 2015
CNS & Neurological Disorders - Drug Targets Change in Body Mass Index Before and After Alzheimer’s Disease Onset
Current Alzheimer Research Olanzapine-Induced Reversible Pellagroid Skin Lesion
Current Drug Safety Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome
Current Alzheimer Research The Place of Pharmacotherapy in Alcohol Use Disorder Management in Family Practice - A Systematic Review
Current Pharmaceutical Design Inhibition of Pyruvate Dehydrogenase Kinase as a Therapeutic Strategy against Cancer
Current Topics in Medicinal Chemistry Evaluating High-Dose Rivastigmine Patch in Severe Alzheimer’s Disease: Analyses with Concomitant Memantine Usage as a Factor
Current Alzheimer Research